Search results
Results From The WOW.Com Content Network
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [2] [33] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials , logistics, and manufacturing.
No participants had received a COVID‑19 vaccine or been previously infected with COVID‑19. [12] The main outcome measured in the trial was the proportion of people who were hospitalized due to COVID‑19 or died due to any cause during 28 days of follow-up. [12] EPIC-HR started in July 2021, and completed in December 2021. [51]
The researchers looked at data on 379 hospitalized infants -- 176 had COVID and 203 had other illnesses -- across 17 states from July 1, 2021, through Jan. 17. Study: Getting COVID Vaccine While ...
In America, the CDC, the American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine encourage pregnant women to get COVID-19 vaccines. [22] The Federation of Obstetric and Gynaecological Societies of India recommend vaccination, though it is not currently recommended by the Government of India. [22]
This photo provided by Pfizer in August 2024 shows a packaging for the company's updated COVID vaccine for ages 12 and up, approved by the U.S. Food and Drug Administration on Thursday, Aug. 22, 2024.
In many countries, including the US, [2] Canada, [3] UK, [4] Australia [5] [6] and New Zealand, [7] vaccination against influenza, COVID-19 and whooping cough is routinely offered during pregnancy. Other vaccines may be offered during pregnancy where travel-related or occupational exposure to disease-causing organisms warrant this.
Pfizer expects about 90% of vaccine sales to occur in the second half, mainly in the fourth quarter. The company expects adjusted EPS of $2.15-$2.35 in 2024 compared with a prior forecast of $2.05 ...
The research that led to nirmatrelvir began in March 2020, when Pfizer formally launched a project at its Cambridge, Massachusetts site to develop antiviral drugs for treating COVID-19. [15] In July 2020, Pfizer chemists were able to synthesize nirmatrelvir for the first time. [15] In September 2020, Pfizer completed a pharmacokinetic study in ...